Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.
One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.
Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.
Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.
Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced an inducement award to Christopher Markey, its new Director of Program and Alliance Management, on June 1, 2021. This award consists of options to purchase 85,000 shares of common stock, having a 10-year term and an exercise price aligned with the closing stock price on the grant date. The options will vest over four years. This compensation was approved by the compensation committee, adhering to Nasdaq regulations, as an incentive for Markey to join the company.
Oncternal Therapeutics (Nasdaq: ONCT) announced a corporate overview presentation at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:30 am Eastern Time. Interested participants can register in advance through a provided link. Following the event, a replay of the presentation will be available on the company's Investors section of the website. Oncternal focuses on developing innovative oncology therapies targeting unmet medical needs, including ongoing clinical trials for cirmtuzumab and TK216.
Oncternal Therapeutics (Nasdaq: ONCT) announced promising interim results from its Phase 1/2 study TK216-01, focusing on TK216 for relapsed or refractory Ewing sarcoma. Two patients achieved complete responses, remaining disease-free for over 24 and 14 months, respectively. The agent displayed a manageable safety profile with no unexpected toxicities. As of April 16, 2021, 68 patients were treated, showing a 9.7% objective response rate and a disease control rate of 45.2%. TK216 received multiple FDA designations, indicating its potential in treating unmet medical needs in oncology.
Oncternal Therapeutics (Nasdaq: ONCT) announced encouraging interim clinical data from the Phase 1/2 CIRLL clinical trial, evaluating cirmtuzumab combined with ibrutinib for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The objective response rate (ORR) was 83% for MCL patients, significantly higher than the historical rate of 66% for ibrutinib alone. The complete response (CR) rate reached 39%, with durability lasting 8-30+ months. Median progression-free and overall survival have not been reached. The safety profile remains consistent with ibrutinib, and enrollment continues.
Oncternal Therapeutics has appointed Salim Yazji, M.D., as Chief Medical Officer to advance its oncology pipeline. Dr. Yazji brings a wealth of experience in oncology drug development and regulatory strategy. His expertise is expected to enhance Oncternal's lead product candidate, cirmtuzumab, and its CAR-T therapy targeting ROR1. As part of his compensation, Oncternal granted Dr. Yazji options to purchase 425,000 shares, with an exercise price equal to the stock's closing price on his appointment date. This move is seen as a crucial step as the company heads toward key clinical trial phases.
Oncternal Therapeutics, Inc. reported promising interim results from a Phase 1b trial of cirmtuzumab combined with paclitaxel for HER2-negative breast cancer, showing a 57% objective response rate (ORR) compared to ~30% historical data. In preclinical studies, cirmtuzumab displayed activity in ovarian cancer cell lines. The company appointed Chase Leavitt as General Counsel and plans to present updates on cirmtuzumab and TK216 at the upcoming ASCO Annual Meeting. Financially, Oncternal reported a $5.9 million net loss for Q1 2021 and has $111.2 million in cash, expected to fund operations into 2023.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the grant of inducement awards to two new non-executive employees on May 3, 2021. Under the 2021 Employment Inducement Incentive Award Plan, the company issued options to purchase 219,400 shares at the closing price on the grant date. These options have a 10-year term and vest over four years. The awards comply with Nasdaq rules and aim to attract talent critical to Oncternal's oncology therapy development.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will announce its Q1 2021 financial results post-market on May 6, 2021. A webcast led by management will follow at 2:00 PM PT (5:00 PM ET) to discuss the results and provide a business update. Oncternal focuses on developing oncology therapies for critical medical needs, with ongoing clinical trials for cirmtuzumab and TK216. The company's pipeline targets significant cancer pathways, including a combination therapy for mantle cell lymphoma and a targeted inhibitor for Ewing sarcoma.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the presentation of two abstracts at the ASCO 2021 Annual Meeting, scheduled for June 4-8, 2021. The oral presentation, titled TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results, will take place on June 4, 2021, while the poster presentation, Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma or chronic lymphocytic leukemia, is set for June 7, 2021. Both investigational therapies target cancer with unmet medical needs and have received various FDA designations, emphasizing their potential in oncology.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) has appointed Chase Leavitt as General Counsel, effective April 12, 2021. Leavitt brings extensive legal experience from leading biotech and technology firms, which is expected to bolster Oncternal's growth trajectory.
Leavitt's responsibilities will include navigating legal compliance and governance as the company develops its ROR1-targeting therapies and other oncology products. He received a B.S. and J.D. from the University of Southern California, adding valuable expertise to Oncternal's leadership team.
FAQ
What is the current stock price of Oncternal Therapeutics (ONCT)?
What is the market cap of Oncternal Therapeutics (ONCT)?
What does Oncternal Therapeutics specialize in?
What are the key products in Oncternal's pipeline?
What is zilovertamab?
What is ONCT-534?
How is Oncternal funded?
What makes ONCT-808 unique?
What is the significance of ONCT-216?
What are the current clinical trials for Oncternal's products?
Where can I find more information about Oncternal Therapeutics?
How does Oncternal aim to address unmet medical needs?
